A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Vortioxetine (Primary) ; Paroxetine
- Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Generalised anxiety disorder; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Takeda
- 22 Jun 2017 Status changed from active, no longer recruiting to completed.
- 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2016 Status changed from not yet recruiting to recruiting.